Dr. Mark W. Ornstein

Internal Medicine
43 Main St, 
Farmingdale, NJ 
43 Main St, 
Farmingdale, NJ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mark Ornstein is a primary care provider, practicing in Internal Medicine in Farmingdale, New Jersey. Dr. Ornstein is rated as an Experienced provider by MediFind in the treatment of Plague. His top areas of expertise are Alzheimer's Disease, Dementia, Unverricht-Lundborg Syndrome, and Lafora Disease.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Internal Medicine
Licenses
Internal Medicine in NJ
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

43 Main St, Farmingdale, NJ 07727

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease
Enrollment Status: Completed
Publish Date: October 29, 2025
Intervention Type: Drug
Study Drug: AL002
Study Phase: Phase 2
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Study Evaluating the Safety and Efficacy of Simufilam 100 mg Tablets in Subjects With Mild-to-Moderate Alzheimer's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Study Evaluating the Safety and Efficacy of Simufilam 100 mg Tablets in Subjects With Mild-to-Moderate Alzheimer's Disease
Enrollment Status: Completed
Publish Date: May 25, 2025
Intervention Type: Drug
Study Drug: Simufilam
Study Phase: Phase 3
A Phase 2A Study to Evaluate Safety, Tolerability and Pharmacological Effects of PU AD in Subjects With Mild Alzheimer's Disease (AD) Dementia
A Phase 2A Study to Evaluate Safety, Tolerability and Pharmacological Effects of PU AD in Subjects With Mild Alzheimer's Disease (AD) Dementia
Enrollment Status: Terminated
Publish Date: November 17, 2022
Intervention Type: Radiation, Behavioral, Diagnostic test, Drug
Study Drug: Dihydrochloride Salt
Study Phase: Phase 2
Effect of LY3202626 on Alzheimer's Disease Progression as Measured by Cerebral ¹⁸F-AV-1451 Tau-PET in Mild Alzheimer's Disease Dementia
Effect of LY3202626 on Alzheimer's Disease Progression as Measured by Cerebral ¹⁸F-AV-1451 Tau-PET in Mild Alzheimer's Disease Dementia
Enrollment Status: Terminated
Publish Date: April 19, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-Blind, Delayed-Start Study of LY3314814 (AZD3293) in Early Alzheimer's Disease Dementia (Extension of Study AZES, The AMARANTH Study)
A Randomized, Double-Blind, Delayed-Start Study of LY3314814 (AZD3293) in Early Alzheimer's Disease Dementia (Extension of Study AZES, The AMARANTH Study)
Enrollment Status: Terminated
Publish Date: December 03, 2019
Intervention Type: Drug
Study Phase: Phase 3
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Enrollment Status: Terminated
Publish Date: December 03, 2019
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: October 10, 2019
Intervention Type: Drug
Study Phase: Phase 3
View 6 Less Clinical Trials

1 Total Publications

Role of Tau Acetylation in Alzheimer's Disease and Chronic Traumatic Encephalopathy: The Way Forward for Successful Treatment.
Role of Tau Acetylation in Alzheimer's Disease and Chronic Traumatic Encephalopathy: The Way Forward for Successful Treatment.
Journal: Journal of neurology and neurosurgery
Published: December 26, 2017
Similar Doctors
Experienced in Plague
Dr. Joseph J. Fins
Internal Medicine
Experienced in Plague
Dr. Joseph J. Fins
Internal Medicine
505 E 70th St # Ht-4, 
New York, NY 
 (41.0 miles away)
212-746-1347
Languages Spoken:
English

Joseph Fins is a primary care provider, practicing in Internal Medicine in New York, New York. Dr. Fins is rated as an Advanced provider by MediFind in the treatment of Plague. His top areas of expertise are Severe Acute Respiratory Syndrome (SARS), Cerebral Hypoxia, Pneumonia, Deep Brain Stimulation, and Gastrostomy.

Experienced in Plague
Dr. Wei G. Zhao
Internal Medicine
Experienced in Plague
Dr. Wei G. Zhao
Internal Medicine
3401 N Broad St, 
Philadelphia, PA 
 (53.6 miles away)
267-808-1845
Languages Spoken:
English
See accepted insurances

Wei Zhao is a primary care provider, practicing in Internal Medicine in Philadelphia, Pennsylvania. Dr. Zhao is rated as a Distinguished provider by MediFind in the treatment of Plague. His top areas of expertise are Microsporidiosis, Lung Adenocarcinoma, Lung Cancer, Coronary Artery Bypass Graft (CABG), and Osteotomy.

Experienced in Plague
Dr. Alexander M. Spring
Internal Medicine
Experienced in Plague
Dr. Alexander M. Spring
Internal Medicine

Montefiore Medical Center

111 E 210th St, 
Bronx, NY 
 (49.6 miles away)
718-920-4321
Languages Spoken:
English
See accepted insurances

Alexander Spring is a primary care provider, practicing in Internal Medicine in Bronx, New York. Dr. Spring is rated as an Experienced provider by MediFind in the treatment of Plague. His top areas of expertise are Plague, Endocarditis, and Transcatheter Aortic Valve Replacement (TAVR).

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ornstein's expertise for a condition
ConditionClose
        View All 7 Experienced Conditions
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile